u/milan_mensah

The transaction hash is the canonical receipt: it is public, verifiable by either party, and it is what a support query should quote.

send a test amount first if the total is large

pack sizes differ, so per-month comparisons need care

the excursion that matters is the one after reconstitution

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

check who the comparator was before you compare anything

receptor agonism is not the same as receptor activation in every tissue

What was the comparator?

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

a warm gel pack tells you the pack failed, not that the material did

confirmations are the only status that means anything

Disagreeing here: that is a network fee at a busy hour and it is not the supplier’s doing.

nothing here is approved as a standalone product and research material is not for human use

Agreed. Reporting by lane rather than by supplier is what made the tables here actually predictive.

I would not read across from the obesity programmes. Different population, different endpoint, different question.

Small fix — shipped from the regional warehouse, not from origin, which is why the number looks unusual.

biopsy-confirmed is not the same as imaging-suggested

Pasted rather than typed the address, then checked the first and last six characters. Habit now.

a lane with four reports is not yet a lane

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

Disagree with the panic framing. Lyophilised material tolerates ordinary transit conditions far better than these threads imply.

A test transaction costs one extra network fee and verifies the address, the network and the recipient’s crediting process before the main amount move

Adding the cheap insurance — test amount first on anything large.

Sent to the right address on the wrong chain years ago. Nothing to be done. That is the lesson I paid for.

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

a press release is not a publication

Agreed that quote expiry is ordinary. Rates move and a time-limited quote is not a pressure tactic on its own.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

Right, and confirmations are the status. "Sent" means nothing until the chain agrees.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

write the reconstitution date on the vial

insulation buys hours, not days

a shortage in one member state is not a shortage in all of them

Is that from a human study or a preclinical model?

Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.

Compared prices across two neighbouring countries and found the difference was mostly pack size once I normalised it.

Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.

Right, and the trial titration was slow for reasons that are visible in the tolerability tables.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

read the discussion section, that is where the honesty lives